Data on nearly 15,000 type 2 diabetes patients revealed the odds ratio for macrovascular events associated with insulin therapy was only 0.53 in those who took one oral glucose-lowering drug, 0.85 in those who took two and 1.07 in those who took three. The findings suggest that using insulin as an add-on to OGLD treatment may not increase the incidence of cardiovascular events, researchers reported in Pharmacoepidemiology and Drug Safety.

Related Summaries